Baseline demographics
| Variable | RCA | LAD | LCx | P values |
| Age, median (IQR) | 66 (58–74) | 66 (57–75) | 65 (57–73) | <0.001 |
| Sex | <0.001 | |||
| Male symptom to FMC time | 7935 (66.6%) | 10 083 (73.5%) | 3122 (74.1%) | |
| Female | 3974 (33.4%) | 3628 (26.5%) | 1090 (25.9%) | |
| Smoking status | <0.001 | |||
| Never smoked | 3762 (35%) | 5523 (45%) | 1412 (37.2%) | |
| Ex-smoker (>1 month) | 2924 (27.2%) | 3083 (25.1%) | 1006 (26.5%) | |
| Smoker | 4076 (37.9%) | 3675 (29.9%) | 1381 (36.4%) | |
| BMI, median (IQR) | 26.2 (23.9–29) | 26.2 (24–28.8) | 26.3 (24.2–29) | NS |
| Clinical presentation | ||||
| Heart rate, median (IQR) | 70 (58–81) | 77 (66–90) | 73 (62–86) | <0.001 |
| Systolic BP, median (IQR) | 138 (120–158) | 140 (120–160) | 143 (125–165) | <0.001 |
| Diastolic BP, median (IQR) | 80 (70–91) | 85 (75–100) | 85 (73–99) | <0.001 |
| Cardiogenic shock | 346 (3%) | 292 (2.2%) | 114 (2.8%) | <0.001 |
| Symptom to FMC time | 2:30 (1:30–4:30) | 2:20 (1:22–4:20) | 3:59 (1:30–4:45) | <0.001 |
| FMC to PCI time, median (IQR) | 1:08 (0:45–1:43) | 1:11 (0:47–1:48) | 1:15 (0:50–2:00) | <0.001 |
| FMC to PCI >1 hour | 6047 (57.4%) | 7283 (60%) | 2391 (63.7%) | <0.001 |
| Previous comorbidities | ||||
| Diabetes | 1910 (16%) | 2260 (16.5%) | 672 (16%) | NS |
| Hypertension | 4675 (39.3%) | 5027 (36.7%) | 1627 (38.6%) | <0.001 |
| Stroke | 658 (5.5%) | 717 (5.2%) | 212 (5%) | NS |
| Kidney failure | 114 (1%) | 98 (0.7%) | 35 (0.8%) | NS |
| COPD | 487 (4.1%) | 420 (3.1%) | 146 (3.5%) | <0.001 |
| Peripheral artery disease | 250 (2.1%) | 203 (1.5%) | 80 (1.9%) | <0.01 |
| Cancer | 250 (2.1%) | 203 (1.5%) | 80 (1.9%) | <0.05 |
| PCI variables | ||||
| Femoral catheterisation | 6736 (56.6%) | 7622 (55.7%) | 2239 (53.3%) | <0.01 |
| DES | 3526 (29.6%) | 5576 (40.7%) | 1473 (35%) | <0.001 |
| MVD | 6011 (50.7%) | 5051 (37%) | 2299 (54.9%) | <0.001 |
| >1 stent | 4274 (35.9%) | 4080 (29.8%) | 1259 (29.9%) | <0.001 |
| Periprocedural medication | ||||
| ASA before PCI | 9967 (83.8%) | 11 281 (82.4%) | 3547 (84.3%) | <0.01 |
| Clopidogrel before PCI | 6422 (54%) | 7268 (53.1%) | 2352 (55.9%) | <0.01 |
| Prasugrel before PCI | 421 (3.5%) | 461 (3.4%) | 125 (3%) | NS |
| Ticagrelor before PCI | 1727 (14.5%) | 1990 (14.5%) | 631 (15%) | NS |
| Heparin before PCI | 3651 (30.7%) | 4132 (30.2%) | 1278 (30.4%) | NS |
| Heparin during PCI | 7166 (60.2%) | 8274 (60.4%) | 2516 (59.8%) | NS |
| Bivalirudin during PCI | 4940 (41.5%) | 5634 (41.1%) | 1775 (42.1%) | NS |
| GPIIb/IIIa antagonists during PCI | 5445 (45.7%) | 6126 (44.7%) | 1817 (43.2%) | <0.05 |
| LMWH during PCI | 1121 (9.4%) | 1413 (10.3%) | 505 (12%) | <0.001 |
| Discharge medications | ||||
| ACEi or ARB | 8725 (74.2%) | 11 249 (83.3%) | 3166 (76.3%) | <0.001 |
| Warfarin or NOAC | 337 (2.9%) | 827 (6.1%) | 128 (3.1%) | <0.001 |
| ASA | 11 340 (96.4%) | 12 787 (94.6%) | 3969 (95.7%) | <0.001 |
| Beta blockers | 10 385 (88.3%) | 12 544 (92.9%) | 3767 (90.9%) | <0.001 |
| Calcium antagonists | 899 (7.7%) | 761 (5.6%) | 308 (7.4%) | <0.001 |
| Diuretics | 1542 (13.1%) | 2766 (20.5%) | 609 (14.7%) | <0.001 |
| Statins | 11 021 (93.7%) | 12 527 (92.7%) | 3872 (93.4%) | <0.01 |
| p2y12 inhibitors | 11 328 (96.3%) | 12 929 (95.7%) | 3977 (95.9%) | <0.05 |
| Clopidogrel | 8654 (73.6%) | 9969 (73.8%) | 3011 (72.6%) | |
| Prasugrel | 300 (2.6%) | 353 (2.6%) | 134 (3.2%) | |
| Ticagrelor | 2351 (20%) | 2580 (19.1%) | 825 (19.9%) | |
| Optimal discharge medication | 7382 (62.7%) | 9875 (73.1%) | 2777 (66.9%) | <0.001 |
| Variable | RCA | LAD | LCx | P values |
| Prehospital CPR | 208 (1.8%) | 508 (3.8%) | 98 (2.4%) | <0.001 |
| Resuscitated cardiac arrest in-hospital | 541 (4.6%) | 747 (5.5%) | 183 (4.3%) | <0.01 |
| New atrial fibrillation in-hospital | 534 (4.5%) | 655 (4.8%) | 199 (4.8%) | <0.001 |
| Bleeding in-hospital | 152 (1.3%) | 139 (1.0%) | 55 (1.3%) | NS |
| Pacemaker | 92 (0.8%) | 63 (0.5%) | 28 (0.7%) | <0.01 |
| LVEF | <0.001 | |||
| LVEF ≥50% | 6401 (67.4%) | 3839 (34.4%) | 2051 (60.8%) | |
| LVEF 40%–49% | 2222 (23.4%) | 3548 (31.8%) | 905 (26.8%) | |
| LVEF 30%–39% | 687 (7.2%) | 2868 (25.7%) | 328 (9.7%) | |
| LVEF <30% | 181 (1.9%) | 911 (8.2%) | 90 (2.7%) |
Percentages represent proportions for each culprit group. Percentages presented represent % within each group. Missing percentages represent % of total study population.
ACEi, ACE inhibitor; ARB, angiotensin receptor blocker; ASA, acetylsalicylic acid; BMI, body mass index; BP, blood pressure; COPD, chronic obstructive pulmonary disease; CPR, cardiopulmonary resuscitation; DES, drug-eluting stent; FMC, first medical contact; LAD, left anterior descending artery; LCx, left circumflex artery; LMWH, low-molecular weight heparin; LVEF, left ventricular ejection fraction; MVD, multivessel disease; NOAC, novel oral anticoagulants; PCI, percutaneous coronary intervention; RCA, right coronary artery.